Novartis (NOVN) PT Set at CHF 90 by Berenberg Bank

Novartis (VTX:NOVN) has been given a CHF 90 price target by equities researchers at Berenberg Bank in a report released on Monday. The brokerage presently has a “neutral” rating on the stock. Berenberg Bank’s price target would indicate a potential upside of 14.83% from the company’s previous close.

A number of other research firms have also issued reports on NOVN. Morgan Stanley set a CHF 92 target price on shares of Novartis and gave the company a “buy” rating in a research note on Thursday, January 25th. JPMorgan Chase set a CHF 84 price target on shares of Novartis and gave the company a “neutral” rating in a report on Wednesday, January 10th. Societe Generale set a CHF 95 price target on shares of Novartis and gave the company a “buy” rating in a report on Wednesday, March 14th. S&P Global set a CHF 91 price target on shares of Novartis and gave the company a “neutral” rating in a report on Thursday, January 25th. Finally, Credit Suisse Group set a CHF 77 price target on shares of Novartis and gave the company a “neutral” rating in a report on Wednesday, January 24th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of CHF 88.60.

VTX:NOVN opened at CHF 78.38 on Monday. Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2018/04/16/novartis-novn-pt-set-at-chf-90-by-berenberg-bank.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply